2021
Transfusion practices for pediatric oncology and hematopoietic stem cell transplantation patients: Data from the National Heart Lung and Blood Institute Recipient Epidemiology and Donor Evaluation Study‐III (REDS‐III)
Goel R, Nellis ME, Karam O, Hanson SJ, Tormey CA, Patel RM, Birch R, Sachais BS, Sola‐Visner M, Hauser RG, Luban NLC, Gottschall J, Josephson CD, Hendrickson JE, Karafin MS, Study‐IV‐Pediatric F. Transfusion practices for pediatric oncology and hematopoietic stem cell transplantation patients: Data from the National Heart Lung and Blood Institute Recipient Epidemiology and Donor Evaluation Study‐III (REDS‐III). Transfusion 2021, 61: 2589-2600. PMID: 34455598, DOI: 10.1111/trf.16626.Peer-Reviewed Original ResearchConceptsInternational normalized ratioBlood Institute Recipient EpidemiologyDonor Evaluation Study-IIINational Heart LungTransfusion practicePediatric oncologyRecipient EpidemiologyHSCT patientsPlasma transfusionRed blood cellsPlatelet countHeart LungHematopoietic stem cell transplantation patientsHematopoietic stem cell transplant patientsMedian international normalized ratioStem cell transplant patientsStem cell transplantation patientsLower INR valuesPre-transfusion HbMedian platelet countMulticenter retrospective studyCell transplant patientsCell transplantation patientsStudy IIIAcute myeloid leukemiaCost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
Goshua G, Sinha P, Hendrickson J, Tormey C, Bendapudi PK, Lee AI. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood 2021, 137: 969-976. PMID: 33280030, PMCID: PMC7918179, DOI: 10.1182/blood.2020006052.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCombined Modality TherapyCost-Benefit AnalysisDecision TreesDrug CostsDrug Therapy, CombinationFemaleFibrinolytic AgentsHemorrhageHumansImmunosuppressive AgentsLength of StayMaleMarkov ChainsMiddle AgedModels, EconomicMulticenter Studies as TopicPlasma ExchangePurpura, Thrombotic ThrombocytopenicRecurrenceRituximabSingle-Domain AntibodiesStandard of CareUnited StatesYoung AdultConceptsIncremental cost-effectiveness ratioThrombotic thrombocytopenic purpuraTherapeutic plasma exchangeVon Willebrand factorRelapse rateThrombocytopenic purpuraClinical trialsMajor randomized clinical trialsThrombotic microangiopathy leadingEnd-organ damageWillebrand factorPlatelet count recoveryRandomized clinical trialsHealth system costsOne-way sensitivity analysesCost-effectiveness ratioLife-threatening diseaseProbabilistic sensitivity analysesCost-effectiveness analysisHospital lengthCount recoveryPlasma exchangeTPE treatmentTTP patientsImmunomodulatory agents
2020
Application of PLASMIC score in prediction of ADAMTS13 deficiency in a pediatric case of acquired thrombotic thrombocytopenic purpura
Gupta GK, Hendrickson JE, Tormey CA. Application of PLASMIC score in prediction of ADAMTS13 deficiency in a pediatric case of acquired thrombotic thrombocytopenic purpura. Journal Of Clinical Apheresis 2020, 35: 140-141. PMID: 31951292, DOI: 10.1002/jca.21767.Peer-Reviewed Original Research
2018
Prevalence and risk factors for RBC alloantibodies in blood donors in the Recipient Epidemiology and Donor Evaluation Study‐III (REDS‐III)
Karafin MS, Tan S, Tormey CA, Spencer BR, Hauser RG, Norris PJ, Roubinian NH, Wu Y, Triulzi DJ, Kleinman S, Gottschall JL, Hendrickson JE. Prevalence and risk factors for RBC alloantibodies in blood donors in the Recipient Epidemiology and Donor Evaluation Study‐III (REDS‐III). Transfusion 2018, 59: 217-225. PMID: 30427537, DOI: 10.1111/trf.15004.Peer-Reviewed Original ResearchConceptsPositive antibody screenDonor Evaluation Study-IIIAntibody screenRisk factorsRecipient EpidemiologyTransfusion historyBlood centersRBC alloantibodiesBlood donorsRed blood cell alloimmunizationCommon antibody specificitiesPrior transfusion historyRBC alloantibody formationSignificant RBC alloantibodiesHistory of transfusionAdjusted odds ratioMultivariable logistic regressionUS blood centersStudy IIIUS blood donorsPotent immune stimulusFuture medical careHealthy US blood donorsPrior transfusionsPrior pregnancyRisk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS‐III) database
Karafin MS, Westlake M, Hauser RG, Tormey CA, Norris PJ, Roubinian NH, Wu Y, Triulzi DJ, Kleinman S, Hendrickson JE, Study‐III N. Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS‐III) database. British Journal Of Haematology 2018, 181: 672-681. PMID: 29675950, PMCID: PMC5991618, DOI: 10.1111/bjh.15182.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAnemia, Sickle CellArthritis, RheumatoidBlood DonorsBlood Group AntigensChildChild, PreschoolDatabases, FactualErythrocyte TransfusionFemaleHumansImmunizationInfantIsoantibodiesLupus Erythematosus, SystemicMaleMiddle AgedMyelodysplastic SyndromesRisk FactorsTransfusion ReactionConceptsRed blood cell alloimmunizationRecipient EpidemiologyRecipients databaseSignificant RBC alloantibodiesNegative antibody screenLargest RBCStandardized registryPositive patientsRBC alloantibodiesAntibody screenICD9/10 codesPatient cohortRisk factorsResponder statusCertain diagnosisBlood typeLarger studyAlloimmunizationRhD statusStudy databaseRespondersPatientsDisease associationsPotential correlatesEpidemiology
2015
Complex regional pain syndrome and dysautonomia in a 14‐year‐old girl responsive to therapeutic plasma exchange
Hendrickson JE, Hendrickson ET, Gehrie EA, Sidhu D, Wallukat G, Schimke I, Tormey CA. Complex regional pain syndrome and dysautonomia in a 14‐year‐old girl responsive to therapeutic plasma exchange. Journal Of Clinical Apheresis 2015, 31: 368-374. PMID: 26011726, DOI: 10.1002/jca.21407.Peer-Reviewed Original ResearchConceptsComplex regional pain syndromeTherapeutic plasma exchangeCRPS patientsLambert-Eaton myasthenic syndromeReflex sympathetic dystrophyRegional pain syndromeMuscarinic M2 receptorsΒ2-adrenergicAdditional immunosuppressionDetectable autoantibodiesLeg painNeuronal surface receptorsPain syndromeSympathetic dystrophyClinical responseVasomotor symptomsMyasthenia gravisReceptor autoantibodiesAppropriate therapyM2 receptorsPlasma exchangeAlbumin replacementMultiple therapiesEffective therapyMyasthenic syndrome
2013
Allergic transfusion reactions to platelets are more commonly associated with prepooled than apheresis components
Xiao W, Tormey CA, Capetillo A, Maitta RW. Allergic transfusion reactions to platelets are more commonly associated with prepooled than apheresis components. Vox Sanguinis 2013, 105: 334-340. PMID: 23802769, DOI: 10.1111/vox.12063.Peer-Reviewed Original ResearchConceptsAllergic transfusion reactionsTransfusion reactionsATR rateApheresis plateletsPlatelet componentsApheresis componentsAcademic medical centerABO mismatchAdverse eventsAntigen exposurePlatelet transfusionsPlatelet countDonor factorsMedical CenterApheresis productsApheresis unitsPlatelet productsStudy periodTransfusionPlateletsSimilar ratesFurther investigationThe Development of a Novel Molecular Assay Examining the Role of Aminopeptidase P Polymorphisms in Acute Hypotensive Transfusion Reactions
Hui Y, Wu Y, Tormey CA. The Development of a Novel Molecular Assay Examining the Role of Aminopeptidase P Polymorphisms in Acute Hypotensive Transfusion Reactions. Archives Of Pathology & Laboratory Medicine 2013, 137: 96-9. PMID: 23276181, DOI: 10.5858/arpa.2011-0466-oa.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdolescentAgedAminopeptidasesAngiotensin-Converting Enzyme InhibitorsBase SequenceBradykininCase-Control StudiesDNA PrimersFemaleGenetic Predisposition to DiseaseHeterozygoteHomozygoteHumansHypotensionMaleMiddle AgedPolymerase Chain ReactionPolymorphism, Single NucleotideTransfusion ReactionConceptsAcute hypotensive transfusion reactionsHypotensive transfusion reactionsACE-IsTransfusion reactionsSingle nucleotide polymorphismsMolecular assaysHarmful adverse effectsPolymerase chain reactionBradykinin degradationPatientsEnzyme inhibitorsBradykinin generationAPP geneNovel molecular assayPilot studyAdverse effectsChain reactionFurther studiesAminopeptidase PXPNPEP2PolymorphismAssaysAPP activitySequencing resultsTransfusion
2009
Improved plasma removal efficiency for therapeutic plasma exchange using a new apheresis platform
Tormey CA, Peddinghaus ME, Erickson M, King KE, Cushing MM, Bill J, Goodrich T, Snyder EL. Improved plasma removal efficiency for therapeutic plasma exchange using a new apheresis platform. Transfusion 2009, 50: 471-477. PMID: 19804570, DOI: 10.1111/j.1537-2995.2009.02412.x.Peer-Reviewed Original ResearchConceptsSignificant adverse eventsCellular countsPatients D-dimerPlasma-exchange programPlasma removal efficiencyTherapeutic plasma exchangePrimary outcome measureFluid balance measurementsComplement cascade activationPatient's coagulationSecondary outcomesAdverse eventsPlasma exchangeAnticoagulant usageD-dimerClinical trialsFluid replacementOutcome measuresFluid balanceCoagulation systemCOBE Spectra platformFree hemoglobinStudy designWaste plasmaNew apheresis deviceAnalysis of transfusion reactions associated with prestorage‐pooled platelet components
Tormey CA, Sweeney JD, Champion MH, Pisciotto PT, Snyder EL, Wu Y. Analysis of transfusion reactions associated with prestorage‐pooled platelet components. Transfusion 2009, 49: 1242-1247. PMID: 19389029, DOI: 10.1111/j.1537-2995.2009.02128.x.Peer-Reviewed Original ResearchConceptsRandom donor plateletsSingle-donor plateletsTransfusion reactionsPlatelet infusionTransfusion-related acute lung injuryCommon adverse eventsPLT productsAcute lung injuryTertiary care hospitalCases of sepsisAllergic transfusion reactionsTransfusion reaction ratesSignificant differencesAdverse eventsLung injuryCare hospitalVolume overloadFebrile reactionsChi-square analysisTotal infusionPlatelet componentsInfusionStudy designP-valuePlatelets